REC 0438

Drug Profile

REC 0438

Alternative Names: REC 0/0438

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Recordati
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Overactive bladder

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Overactive bladder in Italy (Intravesicular, Powder)
  • 29 Jan 2018 Phase-I/II clinical trials in Overactive bladder in Portugal (Intravesicular) (EudraCT2017-000905-19)
  • 01 Dec 2017 Recordati completes a phase I trial in Overactive bladder in Italy, before December 2017 (Recordati pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top